Clinical Trial Update: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the combination of vorinostat, cladribine, and rituximab in patients with mantle cell lymphoma, relapsed chronic lymphocytic leukem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Leustatin (cladribine)
• Rituxan (rituximab)
• Zolinza (vorinostat)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-11-13